<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">402</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2014-10-4-83-86</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL CASE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Organ-sparing treatment for upper urinary tract tumors in the single functioning kidney in the presence of anatomic anomaly</article-title><trans-title-group xml:lang="ru"><trans-title>Органосохраняющее лечение опух олевого поражения верхних мочевых путей единственной ф ункционирующей почки в условиях анатомической аномалии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Roshchin</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Рощин</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Perepechin</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Перепечин</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>Medcraft@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kachmazov</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Качмазов</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute of Urology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «НИИ урологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">51, Third Parkovaya St., Moscow 105425</institution></aff><aff><institution xml:lang="ru">105425 Москва, 3-я Парковая, 51</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2014-12-30" publication-format="electronic"><day>30</day><month>12</month><year>2014</year></pub-date><volume>10</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>83</fpage><lpage>86</lpage><history><date date-type="received" iso-8601-date="2014-12-01"><day>01</day><month>12</month><year>2014</year></date><date date-type="accepted" iso-8601-date="2014-12-01"><day>01</day><month>12</month><year>2014</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/402">https://oncourology.abvpress.ru/oncur/article/view/402</self-uri><abstract xml:lang="en"><p>The main treatment of urothelial carcinoma of the upper urinary tract is organ-sparing surgery. The unavoidability of the latter may be in doubt in unclassified cases (an extensive tumor involvement area of the calycopelvic system in the single functioning kidney and failure to make an adequate optic revision of the zone of interest). Each of these patients requires a special approach at the stage of diagnosis and choice of treatment policy. The paper describes a case of successful organ-sparing treatment for upper urinary tract cancer in the presence of completely doubled right kidney.</p></abstract><trans-abstract xml:lang="ru"><p>Основным методом лечения уротелиального рака верхних мочевых путей являются хирургические органоуносящие вмешательства. В неклассифицируемых случаях (при наличии обширной площади опухолевого поражения чашечно-лоханочной системы единственной функционирующей почки, невозможности полноценной оптической ревизии зоны интереса) неотвратимость органоуносящего хирургического вмешательства может быть подвергнута сомнению. Каждый подобный пациент требует особого подхода на этапе диагностики и выбора лечебной тактики. Представлен случай успешного органосохраняющего лечения рака верхних мочевых путей при наличии полностью удвоенной правой почки.</p></trans-abstract><kwd-group xml:lang="en"><kwd>upper urinary tract involvement</kwd><kwd>urothelial carcinoma</kwd><kwd>organ-sparing treatment</kwd><kwd>double kidney</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>поражение верхних мочевых путей</kwd><kwd>уротелиальный рак</kwd><kwd>органосохраняющее лечение</kwd><kwd>удвоенная почка</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225–49.</mixed-citation><mixed-citation xml:lang="ru">Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225–49.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Raman J.D., Ng C.K., Scherr D.S. et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 2010;57:1072–93.</mixed-citation><mixed-citation xml:lang="ru">Raman J.D., Ng C.K., Scherr D.S. et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol 2010;57:1072–93.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Azemar M.D., Comperat E., Richard F. et al. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: Frequency, risk factors, and surveillance. Urol Oncol 2011;29(2):130–6.</mixed-citation><mixed-citation xml:lang="ru">Azemar M.D., Comperat E., Richard F. et al. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: Frequency, risk factors, and surveillance. Urol Oncol 2011;29(2):130–6.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Duggan B.J., Gray S.B., McKnight J.J. et al. Oligoclanality in bladder cancer: the implication for molecular therapies. J Urol 2004;171(1):419–25.</mixed-citation><mixed-citation xml:lang="ru">Duggan B.J., Gray S.B., McKnight J.J. et al. Oligoclanality in bladder cancer: the implication for molecular therapies. J Urol 2004;171(1):419–25.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Waldert M., Karakiewicz P.I., Raman J.D. et al. A delay in radical nephroureterectomy can lead to upstaging. BJU Int 2010;105(6):812–7.</mixed-citation><mixed-citation xml:lang="ru">Waldert M., Karakiewicz P.I., Raman J.D. et al. A delay in radical nephroureterectomy can lead to upstaging. BJU Int 2010;105(6):812–7.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Руководство по урологии. Под ред. Н.А. Лопаткина: в 3 т. Т.3: Медицина, 1998. 672 с.</mixed-citation><mixed-citation xml:lang="ru">Руководство по урологии. Под ред. Н.А. Лопаткина: в 3 т. Т.3: Медицина, 1998. 672 с.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. McCoy J., Honda H., Resnicek M., Williams R.D. Computerized tomography for detection and staging of localized and pathologically defined upper tract urothelial tumors. J Urol 1991;146: 1500–3.</mixed-citation><mixed-citation xml:lang="ru">McCoy J., Honda H., Resnicek M., Williams R.D. Computerized tomography for detection and staging of localized and pathologically defined upper tract urothelial tumors. J Urol 1991;146: 1500–3.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Planz B., George R., Adam G. et al. Computed tomography for detection and staging of transitional cell carcinoma of the upper tract. Eur Urol 1995;27: 146–50.</mixed-citation><mixed-citation xml:lang="ru">Planz B., George R., Adam G. et al. Computed tomography for detection and staging of transitional cell carcinoma of the upper tract. Eur Urol 1995;27: 146–50.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
